Board of Directors

Chairman of 2cureX AB and 2cureX A/S

Tonni Bülow-Nielsen has extensive medical device and life science experience as Partner (until 2020 he was also Managing Partner and Senior Vice President in the executive leadership group) through more than 16 years in EIFO (Export and Investment Fund of Denmark), previously Vækstfonden. Today Tonni is a Partner in the Medtech and Lifescience team in EIFO for venture investments and manage a significant portfolio of investments through Board positions, value creation and transactions. Before joining Vækstfonden in 2007, Tonni was founder and CEO of DanMed A/S and Nordic Medical Group A/S from 2002-2007.

Tonni lived and worked in USA 1996-2002 as SVP for USA and President of ELA Medical (Canada & South America), a part of the Sanofi Group, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan). Before this he was Business Unit Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical.

His educational background is medical engineering, and he holds an executive MBA from the Scandinavian International Management Institute.

Tonni has been the chairman of 2cureX AB since 2023 and 2cureX A/S since 2023.

Other board assignments

Evosep, Reapplix, TeesuVac, Microshade, Cathvision, Arcedi Biotech and ILS Denmark.

Independence

Independent of management, the company and major shareholders.

Vice-Chairman, CEO and Founder of 2cureX AB and 2cureX A/S

Ole Thastrup (B. 1953) is co-founder of 2cureX. He has been a board member of 2cureX since its inception.

Ole holds a MSc in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also a Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg’s biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fisher BioImage) which was spun out from Novo Nordisk A/S. Ole is the inventor in several families of globally issued patents. He had advised several venture funds and is a member of granting institutions (e.g. Novo Nordisk Foundation).

2cureX share ownership and warrants
4 156 134 shares via own company

Other board assignments
OT311 APS

Independence
Affiliated to management, the company, and major shareholders

Board member and Founder of 2cureX AB and 2cureX A/S

Grith holds a degree of Biomedical Laboratory Science.

Grith has comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies. She is a co-founder of BioImage A/S, spun out of Novo Nordisk and now part of the imaging division of Thermo Fisher Scientific. She was responsible for the development of functional cell-based assays, and for their transfer to partners such as Amersham plc (now GE Healthcare).

2cureX share ownership and warrants
681 708 shares

Board member of 2cureX AB

Nat Hutley is the visionary founder and CEO of Koodos, a London-based strategic advisory and venture capital firm dedicated to empowering businesses committed to positive impact. With a career that spans multiple industries and regions, Nat brings a wealth of experience, entrepreneurial spirit, and a deep understanding of global markets to 2cureX.

Nat’s professional journey began in shipbroking in Australia, followed by a successful transition into commodity trading in the UK. Driven by a passion for growth and new challenges, he spent a decade in Southeast Asia, where he played a pivotal role in pioneering and scaling businesses across the hospitality, recruitment, oil and gas, and renewable energy sectors in Myanmar. Since returning to the UK, Nat has channelled his expertise into founding Koodos, where he oversees operations, strategic advisory, business development, and investments.

His track record of building and scaling businesses, combined with his dedication to impactful ventures, makes him a valuable addition to the 2cureX team as they continue to advance their mission and deliver exceptional outcomes.

Board member of 2cureX AB

Dan Honeywell is an accomplished Tech Founder and Business Leader, with over 15 years of expertise in building, scaling, and advising high-growth companies. He is recognised for pioneering innovations in the UK healthcare sector and deep expertise in category design, with a proven track record in driving substantial business transformations and leveraging AI for global market expansion.

Dan was Founder and CEO of Zedsen, a pioneering UK MedTech company that changed the face of the UK healthcare innovation sector. He exhibited extraordinary leadership and financial understanding, and the company’s valuation soared from a modest inception to an impressive £100+ million in five years. The company was one of the Top 10 fastest-growing companies in the UK.